Protein production services compared: what separates providers once the expression system is fixed, and the terms worth negotiating
Once the expression system is decided, protein production quotes start to look interchangeable, and they are not. Providers differ in which systems they genuinely run at scale, what analytics are inside the price, how they handle a batch that misses specification, and what you own at the end. This page is about reading those differences out of quotes that look similar.
- the FDA cGMP rule that applies once material is destined for a drug product
- Part 211
- the ICH guideline on deriving and characterising cell substrates
- Q5D
- good laboratory practice for nonclinical studies, 21 CFR
- Part 58
Figures in this panel are the rules a contract biologics service is bought and audited against, named from the regulations and guidelines themselves and linked in the sources below. They are identifiers, not prices: BioBricks publishes verified prices for synthesis services only, and does not imply a services index it has not measured.
- 4 vendor service pages verifiedevery figure matched verbatim to the vendor's page
- Quoted and dated, never estimatedlast verification pass 2026-08-24
- 1 service classes coveredeach with measured search demand behind it
Reading the quotes
- Which systems does the provider actually run. Most providers list every expression system and run one or two well. Ask how many projects in your system they completed in the past year and ask to speak to a customer. Capability breadth on a website is not capability.
- What analytics are inside the price. Purity, concentration, identity, aggregate and endotoxin may each be included or extra, and a cheaper quote frequently excludes the analytics that make the material usable. Normalise every quote against the same analytical package.
- Timelines, and what they are measured from. A stated turnaround may run from order, from receipt of materials, or from a successful feasibility stage. Establish the start point and what pauses the clock, because this is where expectations diverge most often.
- What happens when a batch misses specification. Ask directly: who pays, who investigates, and is a repeat included. A provider with a clear written answer has been here before; one that treats the question as hypothetical will negotiate it while you are waiting for protein.
- Ownership and the repeat order. Constructs, cell banks, process descriptions and any improvement made during the work should have their ownership settled in writing before the first batch. This is the leverage point, and it disappears once the project has started.
Staging, even for production
Even for a known process, a small confirmation run before a large batch is usually worth its cost, because it verifies the process in that provider's hands with your materials. Programmes that skip it occasionally lose a full-scale batch to something a small run would have exposed.
Where the protein is new to the provider, a feasibility stage is not optional. A fixed price for an unfamiliar protein is a risk premium you are paying whether or not the risk materialises.
Shipping, storage and arrival
Specify the format, buffer, concentration and shipping condition, and require a temperature record. Protein that arrives thawed is a batch lost, and the conversation about who bears that is much easier when the shipping specification was written down.
Agree acceptance criteria and an inspection window on arrival, so that a problem is identified while the provider still has the retains to investigate it.
Common questions
- How do I compare protein production quotes?
- Normalise them against the same specification and the same analytical package, establish what each timeline is measured from, and ask what happens when a batch misses specification. Quotes that look similar frequently include very different things.
- Does the provider need experience in my expression system?
- Yes, and websites list far more systems than providers run well. Ask how many projects in your system they completed recently and ask to speak to one of those customers.
- Should I do a small run first?
- Usually. A confirmation run verifies the process in that provider's hands with your materials, and it costs far less than losing a full-scale batch to something it would have exposed.
- What should I own at the end?
- The construct, the cell bank, the process description and any improvement made along the way, as agreed in writing before the first batch. After work starts, the leverage to settle it is gone.
Get a shortlist for your project
Browse by service class
Sources
Cite or embed this figure
The median advertised gene synthesis price per base pair in the US research synthesis services market was $0.11 in August 2026, across 4 verified vendor service pages recorded in BioBricks Synthesis Price Index.
Cite as: "BioBricks Synthesis Price Index", updated 2026-08-24, https://biobricks.org/protein-production-services/.